SOAM
NBIX icon

SBI Okasan Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

SBI Okasan Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Buy
+394
New +$58.5K ﹤0.01% 297
2026
Q1 		– Sell
-494
Closed -$71K – 335
2025
Q4 		$71K Buy
+494
New +$71.6K ﹤0.01% 298

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Okasan Asset Management's NBIX Position: Q2 2026 in Review

SBI Okasan Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 394 shares worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #297 among its holdings. This is a return to the name: SBI Okasan Asset Management previously reported a position in NBIX as recently as Q4 2025.

SBI Okasan Asset Management first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. The position peaked at $71K in Q4 2025. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SBI Okasan Asset Management held 394 shares of Neurocrine Biosciences worth $67K as of Q2 2026.
  • Neurocrine Biosciences was a new SBI Okasan Asset Management position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of SBI Okasan Asset Management's portfolio in Q2 2026, its #297 holding.
  • SBI Okasan Asset Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • SBI Okasan Asset Management's Neurocrine Biosciences position peaked at $71K in Q4 2025.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.